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Despite several decades of research into novel brain-implantable devices to treat a
range of diseases, only two—cochlear implants for sensorineural hearing loss and deep
brain stimulation for movement disorders—have yielded any appreciable clinical benefit.
Obstacles to translation include technical factors (e.g., signal loss due to gliosis or
micromotion), lack of awareness of current clinical options for patients that the new
therapy must outperform, traversing between federal and corporate funding needed to
support clinical trials, and insufficient management expertise. This commentary reviews
these obstacles preventing the translation of promising new neurotechnologies into clinical
application and suggests some principles that interdisciplinary teams in academia and
industry could adopt to enhance their chances of success.
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INTRODUCTION
“Brain-computer interfaces” (BCI) and “brain-machine inter-
faces” (BMI) comprise a class of medical devices designed to
restore independent function lost by neurological disease or
injury. The qualifier “direct” implies that some component of the
artificial device is physically implanted into the brain. While the
BCI terminology usually refers to techniques that sense electrical
activity in the brain to determine intended movement with the
goal of restoring independent communication and movement in
patients with paralysis, in principle any device implanted into the
brain that includes electronic components could be considered a
BCI, for example systems to detect and arrest seizures (Stacey and
Litt, 2008) or to restore episodic memory (Hampson et al., 2013;
Sankar et al., 2014). While there has been tremendous interest
in BCIs, including several pilot trials in human patients and an
explosion of publications in the past few decades, the clinical
benefits have remained quite limited. The purpose of this essay
is to address the disconnect between hundreds of laboratories
around the world toiling on BCIs and the thousands to mil-
lions of patients who could benefit from this technology yet are
not.
“Motor” BCIs refer to systems that decode intended movement
and use this decoded information to control some object in the
world: such as a computer to type out text for communication,
turn off and on light switches, navigate with a wheelchair, or
control one’s own body with external powered braces or inter-
nal neuromuscular stimulators. Given several decades of work
on external scalp-EEG based BCIs and nearly a decade since
the first human patient was implanted with a multi-electrode
array to decode motor intent (Hochberg et al., 2006; Lebedev,
2014), what are the limitations holding back this promising
technology from entering the mainstream for clinical care? Sadly,
there is no lack of people paralyzed by spinal cord injury,
stroke, brain injury, muscular dystrophy and amyotrophic lateral
sclerosis. One possible answer would be to counsel patience:
while there are over 300,000 people with sensorineural hearing
loss who have been implanted with cochlear implants, it has
been over seven decades since Djourno and Eyriès showed in
1957, that an inner ear electrode could elicit sound sensations
in a deaf listener (Djourno and Eyries, 1957; Macherey and
Carlyon, 2014). Is there any way we can learn from prior mis-
takes and successes so that the translation cycle may be accel-
erated to bring these therapies to the clinic faster than seven
decades?
TECHNICAL LIMITATIONS
INFLAMMATION/GLIOSIS
Several groups have demonstrated that motor intent can be
decoded from the activity of ensembles of neurons recorded by
microelectrode arrays implanted into the neocortex of paralyzed
people (Hochberg et al., 2012; Collinger et al., 2013). A problem
for chronic recording of single units is that the number and
quality of recordings fall off with time (Suner et al., 2005; Barrese
et al., 2013; Wang et al., 2014). Several explanations have been
posited: the foreign body of the array induces a reactive gliosis
with scarring or inflammation, the device experiences micro-
motion relative to the cell bodies it seeks to record quench-
ing signal to noise, or the device itself fails internally such as
through mechanical breakage of electrodes or electrolytic changes
in surface chemistry altering impedance (Prasad et al., 2014).
Certain groups have attempted to address this device-brain inter-
face problem by altering the microscopic geometry or surface
chemistry of the devices (Sanchez et al., 2006; Moxon et al.,
2007; Sommakia et al., 2009; Frewin et al., 2011; Ceyssens et al.,
2013; Edgington et al., 2013) others have attempted to circum-
vent the problem entirely by focusing analysis on the envelope
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of multi-unit activity or analyzing time series in the frequency
domain, rather than requiring single units to be discriminated
(Dolan et al., 2009; Flint et al., 2013; Lebedev, 2014; Perge et al.,
2014).
CHASING THE NOISE
For motor BCIs there are two learning systems: the mathematical
algorithm that decodes neural activity into motor commands, and
the patient’s brain itself. Unlike alpha motor neurons in the spinal
cord which are “hard-wired” in motor pools to specific sets of
skeletal muscles, the relationship of cortical neurons to external
muscular and somatosensory features is fluid. If the calibration
routines used are too frequent or extreme, then the two learning
systems will fail to converge on a decoding-control solution and
instead will chase the noise, and the paralyzed patient will not
be able make use of the device (Wu et al., 2004). It would be
analogous to attempting to learn to ride a bicycle if the laws of
physics changed with every attempt to pedal.
CALIBRATION AND TECHNICIANS
All types of motor BCI, whether non-invasive scalp EEG or direct
invasive BCI with implanted electrodes, require considerable set
up and calibration with one or more technicians (Sellers et al.,
2010; Taherian et al., 2014). Even in the net-connected age with
telemedicine, the burden of daily calibration becomes so onerous
as to render the motor BCI unfeasible for widespread clinical
application (Rupp, 2014).
CHALLENGING PRECONCEPTIONS
PRECONCEPTION: LESS INVASIVE TECHNOLOGY IS SAFER FOR
PATIENTS THAN MORE INVASIVE TECHNOLOGY
Just because a technology does not involve a surgical procedure
does not mean it is not risky. The balance of risk and benefit
must take into account all aspects of a technology, not simply
whether one cuts into the skin. As an example, while the heart
can be defibrillated and paced by electrodes worn on the chest,
this would be completely impractical for patients to use on a daily
basis. The system had to be implanted to make it useful. While
motor BCIs may not have proved their utility to an equal degree of
implanted cardiac pacemakers, the point is that the focus of device
development should be on the overall net utility: the greater the
potential benefit, the more a given amount of risk could be taken.
In terms of risks, there seems to be significant misunderstanding
on the part of non-clinicians about what procedures pose risks to
patients and what do not. Relative to other neurosurgical proce-
dures, implantation of tiny microelectrode arrays into the surface
cortex is less risky than other common neurosurgical procedure.
Likewise, the daily scrubbing of a patient’s scalp and attachment
of electrode pads has its own risks of skin breakdown and even
fatal cellulitis in patients who have limited mobility and may be
in a constant state of relative immunocompromise (Rupp, 2014).
Patients with quadriplegia invariably already have undergone
surgeries and have percutaneous devices, such as tracheostomy
tubes attached to ventilators and feeding tubes. It would be more
useful and safer for quadriplegic patients if scalp EEG systems
could be rendered as implantable systems: for example, subdermal
grids with wireless telemetry. A minimally invasive approach
would simultaneously address several bottlenecks in application:
it would decrease the risk of skin infection from repeated scalp
electrode application, it would decrease impedance variability
that affects device performance, and it would take out the reliance
on an external technician to physically affix the electrodes every
day to afford useful communication. Conclusion: “Degree of
invasiveness” is not a helpful metric of neurotechnology safety
or utility. Scientists and engineers developing devices should take
a holistic view of how the device affects the patient’s overall
health.
PRECONCEPTION: BCIs WILL NOT BE CLINICALLY USEFUL UNTIL THEY
CAN EXTRACT MORE INFORMATION
Over the past several decades, several groups working on primate
motor neurophysiology have found that the single-unit, ensemble
and local field potential activity of motor areas in the brain
can be “decoded” to yield information about a wide variety of
motor parameters: not only two and three-dimensional end-point
(i.e., hand) trajectory, but also muscle contraction states, pattern
generator and spinal synergy activation states, joint kinematics,
velocity and acceleration, attentional states, sequence and plan-
ning features and somatosensory fields (Carpenter et al., 1999;
Matsuzaka et al., 2007; Stark et al., 2007; Umilta et al., 2007;
Scott, 2008; Zach et al., 2008; Griffin et al., 2009; Vargas-Irwin
et al., 2010; Pruszynski et al., 2011; Saleh et al., 2012; Addou et al.,
2014; Crowe et al., 2014; Kirsch et al., 2014). Information rate,
following the conventions initially developed by Claude Shannon,
have been one popular way of quantifying BCI performance
(Baranauskas, 2014). While elucidating from a basic neurophysi-
ology perspective, these approaches do not axiomatically translate
into device development and clinical utility. Information transfer
metrics that elucidate how single neurons transform sensory and
motor phenomena (Rieke et al., 1997), tend to devolve into
unhelpful distortions of more appropriate performance metrics
(such as task completion time or validated daily living functional
measures; Peckham et al., 2001). From a practical engineering
perspective it would be far better to have one or two degrees of
freedom that could be decoded in a fast, reliable, technician-free
manner, than seven degrees of freedom that were unreliable and
required considerable external supervision to derive (Peckham
et al., 2001; Rupp, 2014). While entropy rates can be constructed
so as to include reliability as a feature, they are usually not
considered in this manner. Another important feature to consider
in addition to reliability is subjective effort. In principle, even
one’s heart rate could be used as input to a BCI: clearly such
a tactic would require considerable mental focus and would
be confounded by environmental distractions (e.g., accidentally
launching oneself in a heart-rate driven wheelchair upon hearing
a horn honk). The farther one moves from the neocortical areas
driving voluntary movement, the more challenging it is for a
patient to acquire and sustain control. While direct BCIs have
been touted for their ability to yield more degrees-of-freedom
and signal complexity, their greatest benefit may in fact be the
fact that voluntary modulation of signals recorded intracranially
from motor areas is most akin to natural movement and hence
is subjectively effortless for the human participant, much as it
is for healthy humans moving their intact limbs. Conclusion:
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The quantity and complexity of information are limited metrics
for BCI translation to clinical application. BCIs will be clinically
useful when they can extract information in a reliable and sub-
jectively effortless manner with minimal calibration or technician
supervision.
PRECONCEPTION: HUMAN PILOT TRIALS FOR DIRECT BCIs MUST RELY
ON VENTURE CAPITAL FUNDING OR RARE FEDERAL OPPORTUNITIES
It usually takes 7 years and costs $40 million to take a final
medical device prototype from bench to bedside. It takes two
to three years of preparation and nearly $6 million just to
launch an initial Investigational Device Exemption (IDE) trial.
What exactly does this money pay for? One component is to
salary support for consultants with regulatory expertise: this
knowledge of the inner workings of the FDA, CE and other
foreign equivalents, does not typically “live” inside academia.
To have any hope of translational success, investigators must
recruit regulatory colleagues who have successful track records of
shepherding novel devices through the IDE process. The upfront
$6 million also pays for “freezing the design” of the device or
fabrication process, establishing clean room Good Manufacturing
Practices, and sending off device prototypes to existing, com-
mercial “testing houses” that can systematically test the toxic-
ity and biocompatibility of the device and its electrical safety
in the hospital environment. While purposefully incorporating
already-approved well-tested materials and fabrication techniques
can reassure regulators, these agencies ultimately require these
additional tests.
The organizational complexity and financial cost of this pro-
cess does not fit into the typical R01 or non-NIH equivalents that
sustain academic neuroscience laboratories. These leave transla-
tional investigators with few options. One is to appeal to spe-
cial multi-center U01, Veteran’s Affairs or other military-based
(e.g., DARPA) multi-million dollar requests for applications. The
FES Center in Cleveland, has been successful in following this
non-commercial multi-center approach for their neuromuscular
stimulator system to restore independent voluntary movement
in veterans with spinal cord injury (Peckham et al., 1988). The
Department of Defense may withdraw funds if performance
metrics aren’t met rendering it difficult to plan appropriately for
multi-year trials. While the National Institutes of Health sponsors
intramural clinical trials, there is not as extensive a track record
for extramural ones devoted to novel devices. In terms of funding
academic-industry partnerships, SBIRs and STTRs are simply not
at the scale of $6 million needed.
The other option is to create a startup neurotechnology com-
pany and apply for funding from angel investors and venture
capitalists. Except for very simple mechanical based neurotech-
nologies (such as a new kind of shunt), few BCI technologies
are at a stage of commercialization potential that render them
appropriate for risk-averse investors. A pilot trial for a BCI may
simply not make any investment sense for the typical venture
capital funding model (Ford and Nelsen, 2014). If anything, a
promising BCI would be more ripe for VC funding after a pilot
trial demonstrated safety and efficacy.
This investigator therefore proposes that federal agencies cre-
ate new funding mechanisms that fill this gap. These funds would
help investigators set up clean room fabrication facilities and
cover the cost of the numerous regulatory-required tests for
the device. Ideally, all members on the study sections for this
putative new mechanism would have some kind of clinical trial
expertise, including physicians, FDA regulators, and scientists or
engineers who have already successfully run human trials on
their own. Given the scale and duration of the funding, and
the fact that sudden withdrawal of funding in the middle of
a trial could potentially risk patient health, thought should be
given to render this new mechanism “sequester-proof ” should
political forces slash funding. Since industry investors would be
the financial beneficiaries of these trials, one approach would
be to set aside transparent pools donated by industry explic-
itly allocated for this novel translational funding mechanism.
Agencies could make this financially worthwhile if they could
eliminate waste and streamline the process, thus increasing the
amount of return for each dollar invested on pilot trial develop-
ment. By pulling actual FDA regulatory officials into these novel
study sections, investigators and future investors would also reap
enormous benefit in the regulatory process with this “insider”
knowledge. Rather than have each BCI team muddle through the
prototype, clean room, standard biosafety/bioelectrical testing,
by itself, this mechanism would have its own streamlined pro-
cess. Conclusion: Leaders in government, industry and academia
should forge new funding mechanisms that can help investi-
gators shepherd promising BCI technologies into pilot clinical
trials to a stage where traditional existing VC and industry
funding make sense and the chances of commercialization were
greater.
PRECONCEPTION: IF A BCI WERE SAFE AND EFFECTIVE, MARKET
FORCES WILL AUTOMATICALLY PROPEL IT TOWARDS WIDESPREAD
CLINICAL USE
Many good ideas may never end up helping patients due to a
variety of reasons as they may not be marketable or may be
badly marketed (Vecht et al., 2010). Despite clear demonstration
of the safety and efficacy of the FreeHand functional electri-
cal stimulation system to help patients with spinal cord injury
(Peckham et al., 1988; Taylor et al., 2002), the small company
commercializing it (NeuroControl) went out of business before
meeting clinical demand. Scientists seeking to bring a promising
neurotechnology from bench to bedside would do well to under-
stand why certain efforts flounder and why others succeed (de Ana
et al., 2013; Pisano, 2006; Galloway, 2007; Fletcher and Bourne,
2012). Neurotechnology ventures need to involve business experts
early (Leuthardt, 2013) to ensure they can navigate issues of
patents, pricing, reimbursement, and multi-year alliances (Pan-
garkar and Hutmacher, 2003; Bergsland et al., 2014). Inventors
must recognize the importance of skilled management (Burns
et al., 2009), and have realistic expectations of how commer-
cialization unfolds (Galloway, 2007; Fletcher and Bourne, 2012).
Translational scientists must learn that: what drives science does
not drive business, there is no single path to commercializa-
tion, “research” and “development” are very different phases, the
market may not exist at the outset, and that customers are the
“ultimate peer review” (Fletcher and Bourne, 2012). Conclusion:
While having a strong safety and efficacy profile is necessary
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for a medical device, it is not sufficient to reach patients in
need. To reach patients, devices must be supported by skilled
management in both startup and established biotechnology com-
panies.
PRECONCEPTION: THE MARKET FOR NEUROSCIENCE MEDICAL DEVICE
APPLICATIONS IS TOO HETEROGENEOUS AND SMALL TO BE WORTH
THE INVESTMENT
Any business from a Fortune 500 company to a corner bodega
can be run poorly or well: the fact that there is more than
one company manufacturing cochlear implants, for a market
of less than a million patients, is testament to the fact that a
device with demonstrable safety and efficacy can be financially
sustainable. Furthermore, both DBS and cochlear implants are
designed to improve quality of life: patients are not expected to
die directly from deafness or tremor. Conclusion: To reach and
benefit patients, safe and effective technologies must be brought
to market by visionary entrepreneurs who have excellent manage-
ment skills and a deep understanding of the clinical neuroscience
landscape.
PRECONCEPTION: THE BRAIN IS TOO COMPLEX: ANY MEDICAL DEVICE
CANNOT SUCCEED UNTIL THE BRAIN IS BETTER UNDERSTOOD
While cochlear and auditory-brainstem implants leverage
neuroanatomical tonotopy to “play” neural structures,
the fundamental mechanism of deep brain stimulators for
movement disorders remains a source of controversy. Medicine
is replete with countless treatments that are used daily to
successfully improve human health despite the mechanism
of these treatments not being understood. The efficacy of
medical interventions is established empirically rather than
mechanistically. Hundreds of medications are used to treat brain-
based conditions (such as schizophrenia and epilepsy) despite
our limited knowledge about the pathophysiology of these
conditions or how particular medications exercise their effects.
Conclusion: Neurotechnoloogy that can concretely help people
can be financially remunerative even despite our incomplete
knowledge of the human brain. Companies can “do well by
doing good” by focusing on concrete quality of life outcome
measures rather than relying on a mechanistic understanding of
neurobiology.
PRECONCEPTION: THE TIME TO APPROACH CLINICIANS AND
PATIENTSWHEN CONSIDERING HUMAN APPLICATIONS OF DIRECT BCI
OR OTHER NEUROTECHNOLOGIES IS ONLY AFTER THE TECHNOLOGY
ITSELF IS FINALIZED AND ANIMAL STUDIES ARE COMPLETED
Development of the Utah array from a research tool restricted
to animal investigation to a clinical intervention in a pilot trial
for human patients, benefited from close, friendly collabora-
tion between engineers designing the device within industry
and academic neurosurgeons. By literally handing prototypes
to experienced surgeons to test in animal models and human
cadavers, engineers could gain immediate feedback about helpful
or limiting design features that no amount of bench work could
reveal (Suner et al., 2005; Som et al., 2014). Conclusion: Scientists
should engage physicians, surgeons and patients much earlier in
the design cycle.
RECOMMENDATIONS FOR IMPROVING NEUROTECHNOLOGY
DEVELOPMENT
BCI translation can be accelerated by tightening the design cycle
with close collaboration between engineers, scientists, surgeons,
regulatory experts, and clinicians.
Basic scientists and engineers are urged to never assume what
risk-safety profiles are needed for a device to help a person: they
should query physicians, surgeons and even potential beneficia-
ries and their families, sooner rather than later to ascertain the
medical context, and should focus their energies on making the
device truly useful.
Engineers and scientists are encouraged to visit the patients
whose their technology is intended to help and understand what
solutions they have deployed now to inform what the new tech-
nology must outperform.
Considerations of safety must be holistic and take into account
the overall clinical context: non-invasive devices are not necessar-
ily safer or more practical than invasive ones.
While metrics such as “degrees of freedom” and “entropy bit
rate” have their utility, to facilitate clinical translation, device
developers should focus on increasing device reliability, decreas-
ing subjective effort, reducing calibration and minimizing techni-
cian supervision.
Leadership in government and industry are encouraged to
consider alternate funding mechanisms that can shepherd tech-
nologies farther towards commercialization.
Scientists, surgeons, engineers and physicians seeking to
commercialize promising neurotechnologies should recruit
entrepreneurs with considerable management skill and a track
record of shepherding devices into profitable commercialization.
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